Principal Investigator
Amel Karaa, MD
Massachusetts General Hospital (MGH)
Total Trials
1
As PI
1
Completed
1
h-index
N/A
Publications
0
Years Active
0
Research Impact
h-index
N/A
Research impact score
Publications
0
Total publications
Trial Results
0
Published trial results
Citations
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Phase 21
Trial Status
Completed1
Role Distribution
Principal Investigator1
PI Rate100%
Activity Timeline
Clinical Trials (1)
An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients
Primary Mitochondrial Myopathy
PrincipalinvestigatorStart date: 2021-05-21
Research Network
Collaboration Network
1 collaborators·0 connections
Network Legend
KOL
Current InvestigatorCO
High-influence CollaboratorCO
CollaboratorClick: view details
Double-click: go to profile
Drag: move node
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Massachusetts General Hospital (MGH)
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
2 similar investigators found
Grainne Gorman, MD
Wellcome Centre for Mitochondrial Research
1 trials
Shared therapeutic areas:
Primary Mitochondrial Myopathy
Worked with same sponsors:
Reneo Pharma Ltd
Similarity Score30%
Grainne Gorman, MD
Newcastle Hospital NHS Foundation Trust
1 trials
Shared therapeutic areas:
Primary Mitochondrial Myopathy
Worked with same sponsors:
Reneo Pharma Ltd
Similarity Score30%
Publications (0)
No publications found for this investigator.
Clinical Trials (1)
Showing 1 of 1 trials
An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients
Primary Mitochondrial Myopathy
All 1 trials loaded